

Disclosures

Personal Commercial (24)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|------------------------------|-------------------------------|--------------------------|-------------------------------|
| <i>Self</i> | | | |
| AstraZeneca Pharmaceuticals | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Baim Institute | Consultant Fees/Honoraria | None (\$0) | General Cardiology |
| Baron and Bud | Other - <i>Expert Witness</i> | Significant (>= \$5,000) | General Cardiology |
| Bayer | Research/Research Grants | Significant (>= \$5,000) | |
| Bayer | Consultant Fees/Honoraria | Significant (>= \$5,000) | Other |
| Cleveland Clinic | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Haemonetics | Research/Research Grants | Significant (>= \$5,000) | Other |
| Hikari Dx | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Idorsia | Research/Research Grants | Significant (>= \$5,000) | Acute Coronary Syndromes |
| Instrumentation Labs | Research/Research Grants | Significant (>= \$5,000) | |
| Janssen Pharmaceuticals, Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Janssen Pharmaceuticals, Inc | Research/Research Grants | Significant (>= \$5,000) | Stable Ischemic Heart Disease |
| Janssen Pharmaceuticals, Inc | Research/Research Grants | Significant (>= \$5,000) | Stable Ischemic Heart Disease |
| LabCorp Drug Development | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Medforce | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Novartis Corporation | Research/Research Grants | Significant (>= \$5,000) | Stable Ischemic Heart Disease |
| Prolocor | Research/Research Grants | Modest (< \$5,000) | Acute Coronary Syndromes |
| Recor | Research/Research Grants | Significant (>= \$5,000) | Vascular Medicine |
| Us WorldMeds | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| US WorldMeds | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Vectra | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Vectra | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Web MD Medscape | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Wolters Kluwer | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|-------------|-------------|-------------|-------------|--------------------------|
| <i>Self</i> | | | | |
| 2019 | Clopidogrel | Third Party | Clopidogrel | Significant (>= \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/22/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 6/22/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 6/22/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 6/22/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.